New York, NY / ACCESSWIRE / November 19, 2014 / NeoStem, Inc. (NASDAQ: NBS) today published a new blog post on The Chairman's Blog, written by the Company's Chief Visionary Officer and Chief Medical Officer of Progenitor Cell Therapy, Dr. Andrew L. Pecora. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his new blog post, Dr. Pecora shared his insights about the initial data for the Phase 2 PreSERVE AMI clinical trial. He commented, "We believe the results are encouraging for the feasibility of continuing development of this therapy." Read the full blog post from Dr. Pecora on TheChairmansBlog.com (http://www.thechairmansblog.com/neostem/andrew-pecora/encouraging-findings-preserve-ami/).

About NeoStem, Inc.

NeoStem is a biopharmaceutical company pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation. www.neostem.com

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com



SOURCE: TheChairmansBlog.com